Clinical trial

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

NCT03401385

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-01-31

PhasePHASE1

Study timeline

Study start (actual)2018-01-31Date precision: day

Registry last updated2026-09-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hormone Receptor Positive Breast Cancerunresolved

Triple Negative Breast Cancerunresolved

Non-small Cell Lung Cancerunresolved

Interventions

Datopotamab Deruxtecan (Dato-DXd)DRUG

Steroid Containing MouthwashDRUG

Non-Steroid Containing MouthwashOTHER

Sponsors & collaborators

Daiichi Sankyo Co., Ltd.lead sponsor

Daiichi Sankyocollaborator

AstraZenecacollaborator

Mapped research locations

New YorkNew York, United States2 BostonMassachusetts, United States2 San AntonioTexas, United States2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 BaltimoreMaryland, United States1 AtlantaGeorgia, United States1 NashvilleTennessee, United States1 Washington D.C.District of Columbia, United States1 FairfaxVirginia, United States1 NagoyaAichi-ken, Japan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03401385 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.